Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy and safety of once-weekly tirzepatide as compared with semaglutide, a selective GLP-1 receptor agonist, are unknown. METHODS: In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg. At baseline, the mean glycated hemoglobin level was 8.28%, the mean age 56.6 years, and the mean weight 93.7 kg. The primary end point was the change in the glycated hemoglobin level from baseline to 40 weeks. RESULTS: The estimated mean change from baseline in the glycated hemoglobin level was -2.01 percentage points, -2.24 percentage points, and -2.30 percentage points with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and -1.86 percentage points with semaglutide; the estimated differences between the 5-mg, 10-mg, and 15-mg tirzepatide groups and the semaglutide group were -0.15 percentage points (95% confidence interval [CI], -0.28 to -0.03; P = 0.02), -0.39 percentage points (95% CI, -0.51 to -0.26; P<0.001), and -0.45 percentage points (95% CI, -0.57 to -0.32; P<0.001), respectively. Tirzepatide at all doses was noninferior and superior to semaglutide. Reductions in body weight were greater with tirzepatide than with semaglutide (least-squares mean estimated treatment difference, -1.9 kg, -3.6 kg, and -5.5 kg, respectively; P<0.001 for all comparisons). The most common adverse events were gastrointestinal and were primarily mild to moderate in severity in the tirzepatide and semaglutide groups (nausea, 17 to 22% and 18%; diarrhea, 13 to 16% and 12%; and vomiting, 6 to 10% and 8%, respectively). Of the patients who received tirzepatide, hypoglycemia (blood glucose level, <54 mg per deciliter) was reported in 0.6% (5-mg group), 0.2% (10-mg group), and 1.7% (15-mg group); hypoglycemia was reported in 0.4% of those who received semaglutide. Serious adverse events were reported in 5 to 7% of the patients who received tirzepatide and in 3% of those who received semaglutide. CONCLUSIONS: In patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks. (Funded by Eli Lilly; SURPASS-2 ClinicalTrials.gov number, NCT03987919.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationDavies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Self-citationGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Self-citationCoskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
Self-citationFrias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Self-citationPratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Cited by
Items 1,801–1,900 of 2,039
From Single-target to System Remodeling:Combination Therapeutic Strategies for Metabolic Diseases
Xie, Z., & Li, J. (2026) · 中国科学基金 · doi:10.3724/bnsfc-2025-0006
Antiobesity Medications and Endoscopic Bariatric Therapies: A Narrative Review
Frankl, L., Kim, L. N., & Popov, V. (2026) · Techniques and Innovations in Gastrointestinal Endoscopy · doi:10.1016/j.tige.2026.250976
Type 2 diabetes does not inevitably shorten life expectancy
Du, H. (2026) · Military Medical Research · doi:10.1016/j.mmr.2026.100029
“Recent years have witnessed major advances in obesity and diabetes pharmacotherapy, such as semaglutide and tirzepatide [8,9].”
GLP-1 receptor and Mitochondria-ER Contact Sites: an emerging mechanism of metabolic regulation
Cruz, P., Puebla-Huerta, A., Troncoso, M. F., Silva-Pavez, E., Hidalgo, Y., & Ahumada-Castro, U. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2026.1826699
“Tirzepatide, a dual GLP-1R and GIP receptor (GIPR) agonist, has demonstrated superior ef fi cacy in glycemic control and weight loss, a result now robustly supported by randomized head-to-head trials (Aronne et al., 2025; Frias et al., 2021).”
Gupta, M., & Shukla, J. (2026) · The Indian Journal of Medical Research · doi:10.25259/ijmr_2041_2025 · Cited by 2
Fang, Q., Zhu, Y., Rao, M., & Liu, P. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1752341 · Cited by 2
Ortiz‐Prado, E., Vasconez-Gonzalez, J., Izquierdo‐Condoy, J. S., & López-Jaramillo, P. A. (2026) · doi:10.2196/preprints.99738
Insights into semaglutide cardiovascular research: Mechanisms, trials, and frontiers
Zhang, J. K., Gao, G., He, M., & Sun, T. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178921
AlRashidi, A. M., & Alhowail, A. H. (2026) · International Journal of Pharmacology · doi:10.31083/ijp49432
Short-term effect of tirzepatide on serum calcitonin in adults with obesity
Angelopoulos, N., Simeakis, G., Androulakis, I., Rizoulis, A. A., Boniakos, A., Mentzelopoulou, P., Korakovouni, A., Zianni, D., Petkova, V., Livadas, S., et al. (2026) · Endocrine · doi:10.1007/s12020-026-04655-y · Cited by 1
Low Weight Loss Response to Incretin Analogs: A Systematic Review
Gaskin, P. S., & Chami, P. (2026) · Obesity Reviews · doi:10.1111/obr.70145 · Cited by 1
Dacon, C., Kale-Pradhan, P. B., & Lipari, M. (2026) · Journal of Pharmacy Practice · doi:10.1177/08971900261449175 · Cited by 1
Cao, B., & Ouyang, M. (2026) · Acta Diabetologica · doi:10.1007/s00592-026-02700-w
Differential Acute Kidney Injury Profiles of GLP-1RAs and SGLT2is: A Network Meta-Analysis
Liang, C.-S., Hsu, C.-C., Chen, J.-J., Hung, C.-M., Zeng, B., Yang, W.-C., Suen, M., Wang, H.-Y., Carvalho, A. F., Stubbs, B., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27094137 · Cited by 2
Kumaran., R., & Mohan., A. (2026) · International Conference on Recent Advances in Electrical, Electronics, Ubiquitous Communication, and Computational Intelligence (RAEEUCCI) · doi:10.1109/raeeucci67649.2026.11504461
Goldenberg, R., Trinacty, J., & Ibrahim, C. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70859
“A randomised controlled trial [15] and indirect comparisons [16, 17] have demonstrated superior A1C lowering and weight loss with tirzepatide versus semaglutide in individuals with T2D.”
The Possible Link Between Tirzepatide and Pulmonary Embolism: A Case Report and a Narrative Review
Arecco, A., Cocchiara, F., & Maggi, D. C. (2026) · Endocrines · doi:10.3390/endocrines7020020
Alourfi, N. M., & Alorfi, N. M. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s575375
Monterrosa-Montes, R. J., Rodríguez-Camargo, R. D., Rodríguez-Cuevas, G., & Álzate-Granados, J. P. (2026) · Revista Colombiana de Cirugía · doi:10.30944/20117582.3016
Alam, A. (2026) · Bangladesh Journal of Endocrinology and Metabolism · doi:10.4103/bjem.bjem_17_26
MAKHMUTOV, A., & Qureshi, F. M. (2026) · Cureus · doi:10.7759/cureus.108868
“Second, semaglutide causes more pronounced gastrointestinal side effects compared to tirzepatide [16], which may contribute to greater caloric restriction and dehydration, increasing ketoacidosis risk.”
AVALIAÇÃO COMPARATIVA DOS EFEITOS ADVERSOS DE TERAPIAS INJETÁVEIS PARA CONTROLE DO PESO CORPORAL
Sousa, M. E. D. D., & Caetano, R. C. D. P. E. S. (2026) · LUMEN ET VIRTUS · doi:10.56238/levv17n60-033
Meftah, A., Yoade, B., Cowart, C., Choi, A., Popoola, O., Afe, O., Efremoff, S., Ezema, C., Johnson, B. O., Lawrence, J., et al. (2026) · Cureus · doi:10.7759/cureus.109089
“More recently, new drugs such as semaglutide and tirzepatide have demonstrated even better efficacy [47,48].”
Amping Up Receptor Balance and Bias: Fine Tuning of Unimolecular Multiagonists
Sürmeli, D., Sicinski, K. M., Dinsmore, T. C., Raman, V. S., Montanari, V., Beinborn, M., & Kumar, K. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00745
Estler, B., Fröhlich, H., Täger, T., Heins, J., Frey, N., & Frankenstein, L. (2026) · International Journal of Cardiology · doi:10.1016/j.ijcard.2026.134560
Adipositas und Diabetes mellitus Typ 2 (Update 2026)
Brix, J. M., Clodi, M., Harreiter, J., Hoppichler, F., Fw, K., Itariu, B.-K., Parzer, V., Resl, M., Schindler, K., Toplak, H., et al. (2026) · Wiener klinische Wochenschrift · doi:10.1007/s00508-026-02706-y
“15mg Tirzepatid eine klare Überlegenheit im Vergleich zu Semaglutid sowohl hinsichtlich HbA 1c ( p = 0,002) als auch Gewichtsreduktion ( p 0,001) gezeigt werden [46].”
Novel tirzepatide: A torchbearer in type 2 diabetes mellitus and obesity
Musaliyar, A., Kumar, N., Terrance, S., Reni, A. R., & Ashwini Aithal, P. (2026) · Journal of Medical Society · doi:10.4103/jms.jms_28_25
Terui, S., Minami, T., Nakamura, K., & Terauchi, Y. (2026) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2026.15.2.249 · Cited by 1
“14 In the SURPASS-J mono trial, mean decreases in SBP and DBP were −6.5 mmHg to −11.0 mmHg and −3.2 mmHg to −5.6 mmHg, respectively, in the tirzepatide groups, compared with −1.4 mmHg and +0.1 mmHg in the dulaglutide arm.”
InfluentialChaparala, P., Rongali, D. A., Khot, M., Rangachari, B., Ahmed, K. U., Suri, S., Greeshma, M., & Shafiq, M. M. (2026) · Cureus · doi:10.7759/cureus.109350
The role of bariatric metabolic endoscopy in 2026 and beyond
Norton, B. C., Ranganath, S., Bhandari, M., & Haidry, R. J. (2026) · Frontline Gastroenterology · doi:10.1136/flgastro-2025-103561
Helsted, M. M., FONNESBECH-WULFF, C. C., Schaltz, N. L., Lund, I. W., Forman, J. L., Nielsen, C. K., Englund, A., Hartmann, B., Vilsbøll, T., Holst, J. J., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00075-6
Prato, S. D., Heine, R. J., Manghi, F. P., Hsia, S. H., Valderas, E. G., Zeytinoglu, M., Razzoli, E., Kiljanski, J. I., Sharma, P., Knights, A. W., et al. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-05602
Self-citationFouad, Y. M., Abdelghany, W. A., & Sheemy, R. Y. E. (2026) · World Journal of Hepatology · doi:10.4254/wjh.v18.i5.118303
Severe Diabetic Ketoacidosis Triggered by Premature Insulin Reduction After Tirzepatide InitiationPreprint
Hussein, K., Muyomba, I., Simon, T., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9669421/v1
Tirzepatide data: safety first is safety always!
Janić, M., Rabbani, S. A., El‐Tanani, M., Rangraze, I. R., Janež, A., Maggio, V., & Rizzo, M. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2026.2681511
Glucagon-Like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease: A Narrative Review
Desai, A., Habib, H., Wahbeh, L., & Farraye, F. A. (2026) · Gastro Hep Advances · doi:10.1016/j.gastha.2026.101023
Le, D., Kilpatrick, M., Kraft, W. K., Grams, M. E., Jaar, B. G., & Shin, J.-I. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.106618
Mi, B., Ding, S., Tian, Z., et al. (2026) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6c00218
TIRZEPATIDA E OS RISCOS DO USO SEM PRESCRIÇÃO MÉDICA
Silva, B. E., Alves, N. D., Francelino, J. D. S., Spaziani, A. O., Eleutério, B. M. G., da Silva, F. S., Gonzaga, D. M. I. D. S., & Franco, R. F. (2026) · Revista de Geopolítica · doi:10.56238/revgeov17n6-005 · Cited by 1
The GLP-1 Ceiling and GIP Dividend
Sun, Y., Lu, Y., & Wang, N. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.02.5136
Салухов, В. В., Galstyan, G. R., Неймарк, А. Е., Samoilov, V. S., Khalimov, Y. S., Karonova, T. L., & Sukhotskaia, N. A. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-155
Tirzepatide for weight and behavior management in a patient with Smith-Magenis syndrome
Liao, X. C., Huang, T., Hong, D. S., & Luo, L. (2026) · JCEM Case Reports · doi:10.1210/jcemcr/luag152
“This dual mechanism provides synergistic effects on glucose and weight regulation, leading to superior outcomes compared to selective GLP-1 receptor agonists in large-scale trials [11-13].”
Heisey, H. D., Gregg, L. P., Verrico, C. D., Villareal, D. T., & Fletcher, T. L. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70913 · Cited by 4
“However, head- to-head trials have not demonstrated lower GI adverse-effect burden than with semaglutide in either T2DM [35] or WM populations [36].”
Skvortsov, V. V., Skvortsova, E. M., & Makhnach, D. A. (2026) · Spravočnik vrača obŝej praktiki (Journal of Family Medicine) · doi:10.33920/med-10-2605-04
Multireceptor modulation in metabolic disease: are more targets better?
Zhang, S., & Lingvay, I. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01136-0
Min, E., Goyette, A., Young, E., Moon, K., Bellini, N. J., & Isaacs, D. M. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0142 · Cited by 1
Incretin-based therapies: Effects on plasma lipids and potential mechanisms
Syed‐Abdul, M. M., & Lewis, G. F. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109057
Builes-Montaño, C. E., Suarez-Rodriguez, A. F., & Alzate-Vinasco, M. A. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01886-0 · Cited by 2
Cagrilintide–semaglutide: a new option for patients with type 2 diabetes
Scheen, A. J. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00129-4
Umińska, J. M., Ratajczak, J. M., Niezgoda, P., Gajda, R., Szarpak, Ł., Kubica, J., & Navarese, E. P. (2026) · Obesities · doi:10.3390/obesities6030038 · Cited by 3
Sugar Addiction and BED: Elucidating Pathological Mechanisms and Therapeutic Strategies
Yang, Y., Yang, Z., & Zhou, Z. (2026) · BIO Web of Conferences · doi:10.1051/bioconf/202623701009 · Cited by 1
GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists
Abid, M., Sheikh, K. S., Ahmad, M. S., & Jiang, H. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s566414
Hailu, K. T., Abriha, F. N., Duguma, Y. M., Haddad, R. R., Liyew, T., & Kasagga, A. (2026) · Cureus · doi:10.7759/cureus.110657 · Cited by 2
“GLP-1 receptor agonists and related incretin-based therapies have reshaped the treatment of type 2 diabetes and obesity, with agents such as semaglutide and tirzepatide demonstrating substantial effects on body weight and cardiometabolic outcomes in clinical trials [5-8].”
Yin, Y., Ma, J. H., Liu, D., Duan, W., Cheng, Z., Jiang, H. X., Zhang, Y., Wu, G., Zhuang, H., Gu, W., et al. (2026) · Med · doi:10.1016/j.medj.2026.101183
Tirzepatide and the Cardiovascular Continuum: Metabolic, Cardiorenal and Heart Failure Evidence
Parlati, A. L. M., Martini, L., Nardi, E., Carluccio, R., Parlati, L. E., Madaudo, C., & Filardi, P. P. (2026) · Clinical Medicine Insights Cardiology · doi:10.1177/11795468261460202 · Cited by 3
Obesity medications versus metabolic bariatric surgery: the debate goes on
Tan, T. M.-M. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00124-5
Patil, M., Piccinini, F., Johnstone, E. K. M., Casari, I., & Falasca, M. (2026) · Bioscience Reports · doi:10.1042/bsr20250114 · Cited by 1
“SURPASS-2 (NCT03987919) confirmed superiority over semaglutide 1 mg, with additional HbA1c reductions of 0.15%–0.45% and additional 2–5 kg weight loss [104].”
InfluentialEffect of emerging antiobesity and antidiabetic drugs on atherosclerosis
Armentaro, G., Severini, G., Pastura, C. A., Scarcelli, M. R., Cassano, V., & Sciacqua, A. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04438-3
Targeting inflammatory pathways in T2DM: Therapeutic interventions
Ali, S., & Jamous, Y. F. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33590-7.00003-4
Xiao-yu, Z., Wu, Q., Lu, H.-L., Xie, J.-J., Zhang, Y., Xu, Y., Guo, M., & Teng, F. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02163-7 · Cited by 2
“…59,352 eligible participants and intervention durations ranging from 26 to 104 weeks, were included in the systematic review and meta-analysis [8, 9, The included studies evaluated semaglutide or tirz-epatide primarily against placebo, other GLP-1 receptor agonists, or insulin-based regimens.”
Stratégies thérapeutiques dans le traitement du diabète de type 2
Bordier, L., & Bauduceau, B. (2026) · EMC - Endocrinologie - Nutrition · doi:10.1016/s1155-1941(25)49531-6
Zeng, B., Hsu, C.-W., Hung, C., Yang, W.-C., Stubbs, B., Chen, Y.-W., Lei, W.-T., Chen, J.-J., Chen, T., Hsu, S., et al. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.104026
Radi, S., Fallatah, A. A., Lugtum, A. M., Alghanem, K. F., Alhammadi, Q. K., Gari, M. A., Alshehri, M. N., & Ahmed, M. E. (2026) · Research Square · doi:10.21203/rs.3.rs-9749792/v1
Qiao, Z., Du, Y., Lou, J., & Qu, Y. (2026) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-026-00998-w
Guo, A., Krishnan, S., Patel, J., Nayeri, R., Chatterjee, D., Srivastava, P. K., & Nayeri, A. (2026) · Next research. · doi:10.1016/j.nexres.2026.102044
Anterior Cutaneous Nerve Entrapment Syndrome From Glucagon-Like Peptide-1 Receptor Agonist Injection
Singh, N., Chaparro, E., Shapiro, J. M., & Husu, E. N. (2026) · ACG Case Reports Journal · doi:10.14309/crj.0000000000002168
Gillikin, A. P., Lee, Y., Varney, C., Dang, J. T., Tsung, A., Nimeri, A. A., & Shin, T. H. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.104033 · Cited by 3
“35 The novelty in the present study lies in its focus on semaglutide and tirzepatide only, representing the most frequently prescribed incretin-based therapies for severe obesity.”
Nagayama, D., Wakamatsu, M., Watanabe, Y., et al. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100291
“It provides superior glycemic control compared to contemporary anti-type 2 diabetic agents, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) [1].”
The systems medicine view of semaglutide: from clinical trials to molecular mechanisms
Vitorino, R. M. P. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2695172
Mady, R., Tafazal, H., Soliman, H., Ramadan, A., & Hajaj, M. (2026) · Cureus · doi:10.7759/cureus.111445
Mazurkiewicz, W., Borecka, Z., Sobczak, A. M., Szymczak, A., Jaworowicz, A., Piasecka, J., Gołembiewski, B., Mulski, G., Manicka, M., & Baranowicz, M. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5166
Carducci, A., Matteo, P. D., Ferri, C., & Grassi, D. (2026) · Cureus · doi:10.7759/cureus.111508
Santulli, G. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-026-00321-4
“…from single-agent GLP-1R agonists, such as semaglutide and liraglutide, to dual GLP-1R/GIPR co-agonists, exemplified by tirzepa-tide, which in head-to-head comparison outperformed semaglutide for weight reduction in the SURMOUNT-5 trial [1] and for glycemic control in the SURPASS-2 trial [6].”
Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases
Chui, Z. S. W., Xue, Y., Wu, X., & Xu, A. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100150
Silva, G. F. S., Costa, D. S. A., Dias, D. L., Santos, J. N., Palma, A. L. D. R., & do Nascimento, A. B. B. (2026) · Research Society and Development · doi:10.33448/rsd-v15i6.51320
Antor, S. A., Mahjabin, & Jewel, G. M. N. A. (2026) · Research Square · doi:10.21203/rs.3.rs-10159812/v1
Simental‐Mendía, L. E., Barragán‐Zuñiga, L. J., & Reyes-Avitia, V. (2026) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-026-00812-6
Alfadda, A. A., Isnani, A. C., Eldin, M. S., Joy, S. S., Awwad, H. M., Othman, O. M., Elkhateb, H., & Domero, K. C. (2026) · Obesities · doi:10.3390/obesities6040046
Qadeer, A., Khalid, M. B., Syed, R., Jain, S., Zakaria, F., Khan, M. H. A., Gohar, N., Shoukat, A., Mortada, I., Hamza, I., et al. (2026) · Diabetes and Vascular Disease Research · doi:10.1177/14791641261465360
Current Options for Kidney Protection: Are Renin–Angiotensin System Inhibitors Still Relevant?
Wong, W. (2026) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2026.151689
Ghusn, W., Fansa, S., Tama, E., Añazco, D., Espinosa, M. A., Villamarin, J. L., Cifuentes, L., Gala, K. S., Hurtado, M. D., & Acosta, A. J. (2026) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2026.02.006 · Cited by 3
Fu, H., & Saltiel, A. R. (2026) · Cell Research · doi:10.1038/s41422-026-01271-3
Metcalfe, R., Yan, Y., Alam, S., Dyrkton, N., Wilbur, J. D., Abdul-Karim, R., & Park, J. J. H. (2026) · Value in Health Regional Issues · doi:10.1016/j.vhri.2026.101666
Purcell, A. R., Longfield, M. S. G., Rodrigo, N., & Glastras, S. J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71063 · Cited by 2
Management of Obstructive Sleep Apnea in People with Type 2 Diabetes
Patel, N., Soliman, M., Majithia, A. R., & Malhotra, A. (2026) · Diabetology · doi:10.3390/diabetology7070128
Zhang, Y., Zhu, B., Peng, B., Wu, P., Zhong, G., Wang, Y., Wang, Z., Feng, X., Tang, D., Peng, D., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70967
Berry, S. A., Goodman, I. R., McNally, E. H., Elliott, J., & Iqbal, A. (2026) · Diabetes, obesity and metabolism · doi:10.1111/dom.71080 · Cited by 1
“Tirzepatide has been demonstrated to be superior in terms of weight loss and glycaemic benefits when compared to semaglutide in type 2 diabetes [11].”
Real‐World vs. Randomized Trial Evidence for Incretin‐Based Therapies: A Narrative Review
Bloomgarden, Z. T. (2026) · Journal of Diabetes · doi:10.1111/1753-0407.70248 · Cited by 1
Anti-Obesity Drugs: The Rising Significance of GLP-1Agonist, Tirzepatide
Agrawal, P. K., & Garg, R. (2026) · Journal of Mid-life Health · doi:10.4103/jmh.jmh_259_25
Geraci, C., Cannarella, R., Morello, V., Paternò, V., Petrina, S. M., Esposito, R., Geraci, G., Condorelli, R. A., Vignera, S. L., & Calogero, A. E. (2026) · Cancers · doi:10.3390/cancers18142212
Obesity and cardiovascular disease: Mechanistic insights and multimodal management strategies
Polu, P. R. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100729
James-Okoro, P.-P., Field, J., Davies, G., Pearce, A., Al‐Sabah, S., Lim, K. N., Ladds, G., Hornigold, D. C., Gribble, F. M., & Reimann, F. (2026) · Peptides · doi:10.1016/j.peptides.2026.171507 · Cited by 1
Niu, X., Zhang, Y., Liu, Y., Zhu, Y. Z., Fang, B., Hu, C., Xu, X., Wang, R. T., Sang, Y., Zhang, Q., et al. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1803814
“…evidence indicates that pharmacotherapy is often accompanied by adverse events, such as hypoglycemia, dementia, and gastrointestinal intolerance (6, 7), whereas lifestyle interventions, such as structured physical activity, are often limited by poor long-term adherence and modest efficacy (8,…”
Labate, A. M., Cimino, E., Giacomelli, L., Ettori, S., Oladeji, O. A., & Agosti, B. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146170 · Cited by 1
Lipska, K. J., Zawack, K., Yan, L., Mutalik, P., Li, J., Gulanski, B., Ioannou, G. N., & Aslan, M. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-05216
Spiazzi, B. F., Zingano, C. P., Colpani, V., & Gerchman, F. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113431 · Cited by 3
Hao, X., Liu, L., Li, P., Lei, C., Tong, Y., Dong, J., Liu, X., Cheng, X., Zhao, J., Min, X., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113437
Mori, Y., Osaka, N., Terasaki, M., Yashima, H., Saito, T., Tanno, D., Ogino, M., Ohara, M., & Yamagishi, S. (2026) · Biomedicines · doi:10.3390/biomedicines14071554
Research Progress of Tirzepatide in Metabolic Diseases
孙, 豪. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1672603
Lari, S. A., Zumot, M. S., & Alrashid, M. A. (2026) · Cureus · doi:10.7759/cureus.112694
“…the treatment-regimen estimand framework (modified intention-to-treat analysis) revealed that tirzepatide, at its maximum dose, significantly outperformed semaglutide monotherapy in mean HbA1c reductions, yielding decreases of 2.30 percentage points and 1.86 percentage points, respectively [4].”
Influential
Metadata
- Authors
- Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K.
- Affiliations
- University of Leicester (GB)
- From the National Research Institute, Los Angeles (J.P.F.); the Diabetes Research Centre, University of Leicester, and the National Institute of Health Research Leicester Biomedical Research Centre — both in Leicester, United Kingdom (M.J.D.); the Dallas Diabetes Research Center at Medical City, Dallas (J.R.); Centro de Investigaciones Metabólicas, Buenos Aires (F.C.P.M.); and Eli Lilly, Indianapolis (L.F.L., B.K.B., B.L., X.C., K.B.).
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-05
- Volume
- 385
- Issue
- 6
- Pages
- 503-515
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177122952
- Cited by
- 2,096
- References
- 25
- Citations by year
- 2026: 526 · 2025: 556 · 2024: 396 · 2023: 351 · 2022: 208 · 2021: 57
- FWCI
- 188.92
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- semaglutide, type 2 diabetes, HbA1c, GLP-1 receptor agonists, GIP/GLP-1 dual agonist, non-inferiority, weight loss, gastrointestinal adverse effects, drug safety, dose comparison, glycemic control, adverse drug reactions, hypoglycemia
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Semaglutide, Blood Glucose, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Gastric Inhibitory Polypeptide, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Metformin, Middle Aged, Nausea, Weight Loss, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.